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Abstract
Background: The Xpert MTB/RIF assay has garnered significant interest as a sensitive and rapid diagnostic tool to
improve detection of sensitive and drug resistant tuberculosis. However, most existing literature has described the
performance of MTB/RIF testing only in study conditions; little information is available on its use in routine case finding.
TB REACH is a multi-country initiative focusing on innovative ways to improve case notification.
Methods: We selected a convenience sample of nine TB REACH projects for inclusion to cover a range of
implementers, regions and approaches. Standard quarterly reports and machine data from the first 12 months of
MTB/RIF implementation in each project were utilized to analyze patient yields, rifampicin resistance, and failed tests.
Data was collected from September 2011 to March 2013. A questionnaire was implemented and semi-structured
interviews with project staff were conducted to gather information on user experiences and challenges.
Results: All projects used MTB/RIF testing for people with suspected TB, as opposed to testing for drug resistance
among already diagnosed patients. The projects placed 65 machines (196 modules) in a variety of facilities and
employed numerous case-finding strategies and testing algorithms. The projects consumed 47,973 MTB/RIF tests. Of
valid tests, 7,195 (16.8%) were positive for MTB. A total of 982 rifampicin resistant results were found (13.6% of positive
tests). Of all tests conducted, 10.6% failed. The need for continuous power supply was noted by all projects and most
used locally procured solutions. There was considerable heterogeneity in how results were reported and recorded,
reflecting the lack of standardized guidance in some countries.
Conclusions: The findings of this study begin to fill the gaps among guidelines, research findings, and real-world
implementation of MTB/RIF testing. Testing with Xpert MTB/RIF detected a large number of people with TB that routine
services failed to detect. The study demonstrates the versatility and impact of the technology, but also outlines various
surmountable barriers to implementation. The study is not representative of all early implementer experiences with
MTB/RIF testing but rather provides an overview of the shared issues as well as the many different approaches to
programmatic MTB/RIF implementation.
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Background
Each year an estimated 8.6 million people worldwide
develop tuberculosis disease (TB), yet fewer than 6 million
cases are reported and treated [1]. In addition, of the
more than 300,000 estimated multidrug-resistant TB cases
among all notified cases, less than a third were reported in
2012 [1]. One of the impediments to improving case
detection and early initiation of treatment for both drug-
sensitive and-resistant TB is the limited availability of
sensitive and rapid TB diagnostics.
In December 2010, the World Health Organization
(WHO) endorsed the use of the Xpert MTB/RIF® assay
(MTB/RIF) for the detection of TB and rifampicin resis-
tance [2]. The assay uses a closed cartridge that simply
requires insertion into a GeneXpert machine, with similar
infection control laboratory interventions as those for
smear microscopy [3]. These characteristics allow place-
ment of the system at lower level health facilities (e.g. dis-
trict or sub-district facilities), which should theoretically
improve access to testing. A multi-country demonstration
study documented high levels of sensitivity and specificity
to detect Mycobacterium tuberculosis bacteria and rifam-
picin resistance [4], while a recent Cochrane systematic
review supported the initial demonstration study’s findings
[5]. WHO recommends using the MTB/RIF assay as a pri-
mary diagnostic test for persons suspected of having a
DR-TB or in settings with high HIV prevalence and, where
resources permit, as a second test for those with an abnor-
mal chest x-ray (CXR) and/or negative smear microscopy
results [2].
Globally, there has been significant interest in using
the MTB/RIF test across a variety of settings, with over
2.3 million Xpert® MTB/RIF cartridges procured in the
public sector through March 2013 [6]. Various studies
have documented use of the MTB/RIF test in people with
signs and symptoms of TB, on clinical specimens [7-11],
and for the detection of drug resistance [12,13]. Several
commentaries, cost-effectiveness studies and models have
presented potential uses for and likely impacts of this
assay [14-21]. However, there is a dearth of published
literature produced by implementers of the technology in
programmatic settings. As National TB Programs (NTPs)
and their partners scale up the use of MTB/RIF tests for
case detection, there is a need to share results from imple-
mentation in programmatic settings, especially since there
is evidence that research studies and product inserts often
provide a more optimistic view of test performance, as
compared to real-world implementation [22].
TB REACH, a global initiative of the Stop TB Partner-
ship [23], has supported many partners with GeneXpert
technology through its competitive grant making process.
We present results from nine TB REACH interventions,
review the main challenges experienced and formulate
recommendations for other early implementers.
Methods
During the period from September 2011 to March 2013, a
total of 30 TB REACH grants across 24 countries desig-
nated funds to procure GeneXpert machines and the
Xpert MTB/RIF assay. Of these, a convenience sample of
nine projects was selected for inclusion in this study with
the aim of covering a range of implementers, regions and
approaches. Standard quarterly reports from projects were
utilized to analyze MTB/RIF testing data for patient yields,
rifampicin resistance patterns and failed tests. The pro-
prietary files were directly exported from the GeneXpert
Dx software to verify data in quarterly reports. The data
presented reflect the first twelve months of MTB/RIF
assay implementation for each project. The start date of
each project was different; however all data were collected
between October 2011 and March 2013.
All projects completed an electronic questionnaire cove-
ring procurement and deployment experiences, diagnostic
algorithms, training requirements, and recording and re-
porting issues. The questionnaire was followed up by
semi-structured interviews with staff from each project
either in person or over the phone. Interviews with the
manufacturer were also conducted, addressing aspects of
procurement. Questionnaire and interview data were
analyzed for major themes across different aspects of
MTB/RIF assay implementation.
Records utilized were from standard NTP data collected
in the course of routine programmatic implementation
with no personal identifiers. Therefore ethical review for
this analysis was not sought. Individual projects in The
Democratic Republic of Congo (DRC), Kenya, Pakistan,
Bangladesh and Mozambique had waivers for their pro-
jects. The remaining projects in Cambodia, Malawi and
Nepal were being implemented by or on behalf of NTPs




The projects were often the first implementers of the
MTB/RIF test for TB case detection in their respective
countries. Table 1 provides an overview of the selected
nine TB REACH projects including location and case
finding strategy. Placements included public and pri-
vate hospitals and lower primary care facilities, private
diagnostic laboratories, HIV centres, prisons, reference
laboratories and mobile units. The projects were able to
run the machines at district hospitals and at lower levels
of care although in only a few situations were peripheral
microscopy centres included, mostly because of through-
put concerns. Additional files 1,2,3,4,5,6,7,8,9 show pic-
tures of a number of the places where MTB/RIF was
used. A number of interventions initially projected low
MTB/RIF testing numbers due to the high cost of assay
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cartridges and the fact that the test was a new technology.
In these instances, less expensive and lower-capacity
2-module machines were procured rather than standard
4-module units (see Table 2 for recommendations).
The projects consumed on average 979 tests per four-
module machine per year (range 675 in Moldova-1849 in
Cambodia). Theoretically a 4-module machine could run
4,000 tests a year (four tests per module/day, and 250
working days a year). However, several factors impacting
utilization were identified: the number of hours laboratory
technicians were available to work (frequently only 4–5
hours per day), available power supply during the day, the
number of people with suspected TB attending the facility,
and the selectivity of the testing algorithm and case fin-
ding approach. For example, Cambodia only tested 4 days
a week due to mobile clinic logistics and travel.
Algorithms and case finding approaches
A wide variety of diagnostic algorithms incorporating
MTB/RIF testing were implemented (Table 3). Several
projects employed multiple algorithms, though the ma-
jority used the MTB/RIF assay as a second test for
patients with negative smear microscopy results. Some
projects used active case finding strategies, others used a
passive approach. Funding requirements of TB REACH
focused all MTB/RIF testing on patients with suspected
TB, as opposed to already-diagnosed patients suspected
of having DR-TB. In practice however, a number of pro-
jects reported use of a small number of MTB/RIF tests
as drug sensitivity test (DST) in specific cases. All pro-
jects tested pulmonary samples only, and while some
projects accepted samples from children, very few chil-
dren were tested due to difficulties in getting quality
sputum samples.
The majority of projects used some sort of referral sys-
tem to increase the numbers of people tested (Table 1).
None of the projects systematically provided the MTB/RIF
assay as a primary diagnostic test for people with HIV.
Although many sites had ART clinics in their facilities, the
majority of people tested were not from HIV centres, and
the HIV status of those being tested with the MTB/RIF
assay was often unknown.
Time to diagnosis
Table 3 presents an overview of the time needed for a
patient to receive results of an Xpert MTB/RIF test. In
four of the projects the intent was to provide results the
same day and initiate treatment. This was generally im-
plemented except when the number of samples exceeded
machine throughput. Other projects used algorithms
and/or referral systems that improved the standard turn-
around time for bacteriological tests, but were not the
same day. Turnaround times ranged from same day to
over a week when a referral system was in place and/or
Table 1 Overview of early Xpert MTB/RIF test placement and TB case finding strategy in nine countries
Country WHO Country
classifications




Bangladesh HBC, HDR Two urban private diagnostic laboratories 2 Systematic screening of all
attendees
Cambodia HBC Both machines used at one-day mobile camps
set up at primary care facilities
2 Active with promotion of testing
days in community
DR Congo HBC, HDR, HTH One primary care center, one sub-district hospital,
five district hospitals and one provincial laboratory.
7 1 Primarily passive but with employed
community groups to refer people
with suspected TB
Kenya HBC, HTH Two district hospitals and one health center. 3 Mixed, employed community
cough workers to augment numbers
of people testedAll had ART delivery
Malawi HTH One central hospital, four district hospitals, one
health center in a district with no district hospital,
one mission hospital and one community hospital.
8 Passive
Moldova HDR 17 in public facilities at lowest level for TB diagnosis,
two in regional AIDS centers, two in the national
reference laboratory, two in the regional reference
laboratory, and two in the penitentiary sector
16 9 Passive
Mozambique HBC, HTH Four district hospitals 4 Passive
Nepal HBC Four regional hospitals (two public and two private),
one district hospital, two primary health centers, one
private referral center, and one reference laboratory
3 6 Primarily passive with some
awareness raising/and educational
activities to improve numbers
of people tested
Pakistan HBC, HDR Four urban private diagnostic laboratories 4 Systematic screening of all attendees
HBC = High Burden Country, HDR = High MDR-TB Burden Country, HTH = High TB/HIV Burden Country.
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Table 2 Challenges and recommendations for programmatic implementation of Xpert MTB/RIF testing
Implementation area Challenges Recommendations
Machine utilization Overestimation of testing numbers and underutilization
of machine capacity.
Conduct a needs assessment that includes the current number of
people with suspected TB tested at the facility, the need for a
referral system and the impact of the proposed testing algorithm
on testing numbers.
Two-module machines may be a less expensive alternative in
many settings.
Testing algorithms Lack of national guidance on testing algorithms and
use of questionable testing strategies.
To improve yield and reduce cartridge use, consider screening
with CXR.
Consider elimination of smear microscopy as a first test to reduce
delay, loss to follow-up, and avoid repeat testing of most individuals
due to large proportion of smear negative results.
Time to diagnosis Sputum transport systems and testing algorithms can
prolong delay between sputum submission, results and
treatment initiation.
Xpert MTB/RIF testing sites should be located as close to the
patient as possible to allow for rapid treatment initiation keeping
in mind throughput and electrical power limitations.
Referral networks can help utilization rates but can also be costly
to maintain.
Procurement Short shelf life of cartridges, use of machine beyond
date of needed calibration, unanticipated extra costs of
shipping and customs clearance, local procurement
agent not always helpful.
Stagger cartridge shipments to avoid stock outs and expiry.
Plan for module calibration by ordering test kits early.
Plan for extra costs associated with shipment and customs
clearance.
Training Staff rotation and new practices around request forms,
specimen transport and clinical decisions for rifampicin
resistant results.
Testing can be easily done by well-trained lay workers to support
laboratory staff.
The manufacturer has conducted web trainings via
videoconference and webinars and has released a web-based




UPS (15 minutes) Cepheid offers is inadequate in many
settings. Most laboratories need some infrastructure
improvements to allow proper testing.
A standard 800-2000VA inverter and a 12 V/120-200 AH battery
provided power for over 6 hours to one four-module GeneXpert
machine and a laptop (200 wattage required). As a general rule, a
10AH battery will be able to power a requirement of 100 watts per
hour, but more AH are needed when the discharge is over a short
period of time (less than 20 hours). These can be procured locally.
Failed tests Differences between types of failed tests are unclear
and available data not always used.
Error results are coded by the machine and should be
documented. The .gxx files can provide this information and the
types, reason, locations, and technicians associated with the error
should be tracked.
High failed test rates in certain projects. No result test results are often caused by a power failure.
Invalid results are not caused by testing a specimen of insufficient
volume or one which contains saliva the way poor sputum quality
is defined in a NTP. Rather, they seem to be caused by other
problems with sputum. Emphasizing correct sputum collection
techniques, including mouth rinsing to remove food or particles
which could inhibit the assay, may help reduce Invalid results, as
well as improve yield.
Drug resistance Some confusion about clinical decisions after receiving
rifampicin resistant and indeterminate results.
Patients with indeterminate results have TB, but rifampicin
resistance cannot be confirmed due to a very low burden of TB
bacilli in the specimen. Unless there is documented DR-TB risk,
first-line treatment can be started. Follow-up of these patients is
warranted.
Trepidation over Xpert MTB/RIF use overburdening
DR-TB programs.
The majority of drug-resistant cases in almost all
countries will be found among new cases, requiring testing of
people with suspected TB rather than
patients already in TB treatment.
Patients with rifampicin resistance will be detected in greater
numbers and with greater speed than under current conditions,
and significant resources and coordination will be required.
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the sample was transported from a remote facility. At
sites that used referral systems, most testing was con-
ducted on people presenting at the facilities rather than
on sputum transported through referral systems. This
diagnostic timeline still appeared to represent a shorter
time to treatment for those with smear negative but
MTB-positive results compared to initiative treatment as
a smear negative case, but it was difficult to measure. In
Moldova however, where parallel smear microscopy was
conducted for all people with suspected TB, among
those with MTB-positive results, only 56% were positive
by smear microscopy. This led to immediate treatment
for a large proportion of people who otherwise would
have had to wait for CXR and/or culture results before
treatment could begin.
In Cambodia and for hospitalized patients in Malawi,
MTB/RIF tests were performed on the same day that
sputum was submitted but, due to the number of indi-
viduals indicated for testing and laboratory work load,
some had to wait to receive their results until the fol-
lowing day. In Pakistan, Bangladesh, Mozambique and
Kenya, smear microscopy and, if indicated, MTB/RIF
Table 2 Challenges and recommendations for programmatic implementation of Xpert MTB/RIF testing (Continued)
Recording and
reporting
Supplied GeneXpert Dx software is not appropriate for
analyzing patient cohorts, many times failed tests are
recorded on paper with a generic error ‘result’,
underreporting of errors, lack of clear guidance from
national programs on recording and reporting of cases
identified by Xpert MTB/RIF.
Dissemination and uptake of WHO guidelines on recording and
reporting should be adopted by countries and their NTPs.
Automated reporting mechanisms can improve both the
timeliness and accuracy of reporting as well as assist in supply
chain management.









screen to Xpert + result
Time from submission
of sputum for Xpert
MTB/RIF test to result
Bangladesh A - Direct to Xpert for
all with history of
previous TB treatment
POC Automatic in laboratory 0-1 day Same day
B - Xpert following





POC Automatic in laboratory 0-1 day 0-1 day
DR Congo Xpert following
SS- results
Both, using a hub and
spoke transport system to
augment testing numbers
After follow up tests
and review
7-10 days 1 day
Kenya Xpert following
SS- results
Both, using a hub and
spoke transport system to
augment testing numbers
Automatic in laboratory
for those with negative
smear results
1-4 days 1 day
Malawi A - Direct to Xpert for all
hospitalized patients
with suspected TB
Both, using a hub and
spoke transport system to
augment testing numbers
Automatic in laboratory
for those with negative
smear results
1 day for walk in
patients and up to




Moldova Direct to Xpert; parallel
smear microscopy
POC at most facilities;
referral at AIDS Centers
Automatic in laboratory 0-1 days 0-1 days
Mozambique Xpert following
SS- results
Referral Automatic in laboratory
for those with negative
smear results




SS- results and a
suggestive CXR
Both, using a hub and
spoke transport system to
augment testing numbers
After follow up tests
and review
1 day for walk in patients
and up to 10 days for
referral patients
1-2 days
Pakistan A - Direct to Xpert for all
with history of previous
TB treatment
POC Automatic in laboratory 0-1 day Same day
B - Xpert following
SS- results and TB
Suggestive CXR
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testing, were performed on a single sputum specimen sub-
mitted by each presumptive TB patient, shortening the
time from sputum collection to MTB/RIF results. The
DRC project reported a wide variance of times to diagno-
sis depending on the length of time it took to transport
samples from peripheral microscopy laboratories. Malawi
used a referral network including community sputum
collection points and microscopy centres with two deli-
veries per week to augment the number of people tested.
Mozambique also used a hub system, although systems
to transport and process referred samples were difficult
to maintain over time. Measures taken to reduce turn-
around-time included using the same specimen to per-
form smear microscopy and the MTB/RIF test, training
lab technicians to automatically conduct the MTB/RIF
tests following smear-negative results (as opposed to
waiting for a referral form), and paying for extra human
resource support for laboratory staff.
Preparation and installation requirements
Procurement and service
For all projects, procurement was done through the Global
Drug Facility, with cartridges shipped in two or three
batches to compensate for the short shelf life of the pro-
duct in 2012 (8–12 months). The median lead time (order
placement until delivery to port of entry) for ordering
machines and test cartridges was 40 days (range 12–62).
Shipping costs added to the test cost and ranged from
0.33 USD to 1.44 USD per test.
Following the cartridge price reduction in July 2012
from USD 16.68 to USD 9.98 [24], a number of shipments
were delayed due to a surge in orders from countries that
had postponed ordering to benefit from the price reduc-
tion. This resulted in a backlog of orders that could not be
met by Cepheid’s production capacity at that time. In
addition, a manufacturing problem lowered production
capacity in the Winter and Spring of 2012–13 [25]. As of
July 2013, the cartridge shortage issue had been resolved.
Cepheid has agreements with local service providers in
different countries which are intended to assist in pro-
curement, service and repair needs. The experience of
projects with these providers was quite varied and some
local providers were found to be severely inadequate. As
increasing Xpert MTB/RIF testing occurs, the demand for
competent in-country services will also increase. Identi-
fying competent and responsive local providers will be
necessary for scale up efforts.
Training/human resource issues
Many projects mentioned that when placing machines in
more peripheral sites, training in how to use a computer
was more difficult than training for the test procedure
itself. Several also reported that the lack of multi-language
settings for the GeneXpert Dx software was a challenge,
particularly in settings where the Roman alphabet is
not used. Implementers employed a range of people to
manage GeneXpert equipment, including lay workers, TB
staff, general laboratory staff and new project hires. Prior
laboratory experience is not required to competently use
the assay (Table 2). Pakistan, which employed lay indivi-
duals to perform testing, had one of the lowest failed test
rates of the projects (Table 4). All projects reported high
levels of laboratory staff satisfaction with the machine, its
ease of use, the ability to complete other tasks while tes-
ting, and rapid test results.
The programmatic aspects of implementation, including
clinical decisions on testing, completion of MTB/RIF
request forms, transportation of specimens, and registe-
ring results and treatment decisions, especially in cases of
rifampicin resistant results, required the most training.
Infrastructure and power supply
In most cases, local infrastructure improvements to ad-
dress issues of climate control, work space security, ventila-
tion, and dust control were required to set up GeneXpert
equipment. Procurement needs included air conditioners
or heaters, fans, safety equipment, and in a couple of
instances, refrigerators for stored samples. The main im-
provement required was for uninterrupted power supply
to complete each test. Although the manufacturer offers
an uninterrupted power supply (UPS) device for each
GeneXpert machine, additional protection is often needed
as said UPS was developed for high-income settings with
relatively stable power supplies. In Cambodia, a generator
was used for machines in mobile clinics (Additional files
8,9). Many projects used locally sourced power solutions
including inverters and large backup batteries at costs
comparable to or lower than the UPS supplied by the
manufacturer (300–900 USD). See Table 2 for recommen-
dations on UPS specifications and Additional files 5,6,7,8
for images. The laptop’s built-in battery drains the UPS
less quickly than a desktop and may result in fewer failed
tests; however, laptops may be more vulnerable to theft.
The four-module desktop machine costs 17,000 USD
(500 USD less than a laptop unit).
Test results
Overall results
Over the first 12 months of implementation the nine pro-
jects consumed 47,973MTB/RIF tests (range 1,428-11,472).
MTB/RIF testing resulted in a positive test for 15.0%
(7,195) of all cartridges used and for 16.8% of all valid tests
(excluding failed tests). Positivity among valid results
varied between 10.1% and 23.6% (Table 3). Due to the
wide variety of diagnostic algorithms used by the different
projects, it is difficult to directly compare yields across
sites. The yield of TB cases at sites utilizing CXR as a
screening test and/or using Xpert MTB/RIF as the first
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Table 4 Result data from first 12 months of Xpert MTB/RIF implementation in nine countries
Xpert site Tests MTB Positive Rifampicin Failed Tests Type of failed test MTB +w/o
failed testsN % Sensitive Indeterminate Resistant n % Error Invalid No result
n % N % n % N % n % n %
Bangladesh 1428 286 20.0% 249 87.1% 11 3.8% 26 9.1% 99 6.9% 85 85.9% 10 10.1% 4 4.0% 21.5%
Cambodia 3697 768 20.8% 741 96.5% 22 2.9% 5 0.7% 439 11.9% 169 38.5% 264 60.1% 6 1.4% 23.6%
DR Congo 6348 567 8.9% 498 87.8% 17 3.0% 30 5.3% 1032 16.3% 868 84.1% 107 10.4% 57 5.5% 10.7%
Kenya 2803 258 9.2% 238 92.2% 11 4.3% 9 3.5% 266 9.5% 240 90.2% 23 8.6% 3 1.1% 10.2%
Malawi 6258 632 10.1% 602 93.5% 9 1.4% 21 3.3% 853 13.6% 546 64.0% 265 31.1% 42 4.9% 11.7%
Moldova 11472 1965 17.1% 1227 62.4% 48 2.4% 690 35.1% 673 5.9% 387 61.7% 105 15.6% 181 26.9% 18.2%
Mozambique 6823 910 13.3% 826 90.8% 18 2.0% 66 7.3% 871 12.8% 521 59.8% 216 24.8% 134 15.4% 15.3%
Nepal 6943 1376 19.8% 1257 91.4% 14 1.0% 105 7.6% 744 10.7% 409 55.0% 148 19.9% 187 25.1% 22.2%
Pakistan 2201 433 19.7% 390 90.1% 13 3.0% 30 6.9% 130 5.9% 77 59.2% 37 28.5% 16 12.3% 20.9%
All Countries 47973 7195 15.0% 6028 83.8% 163 2.3% 982 13.6% 5107 10.6% 3302 64.7% 1175 23.0% 630 12.3% 16.8%
South Africaa 1180669 171792 14.6% 155811 90.7% 2443 1.4% 12266 7.1% 32561 2.8% 15.0%




















test (Bangladesh, Cambodia, Moldova, Pakistan) was
50-70% higher than sites which went straight from smear
microscopy to the MTB/RIF test (Kenya, Mozambique,
DRC). The overall positivity in these 9 projects was similar
to yields from the South Africa’s rollout of Xpert MTB/RIF
(15%) [26]. Among all MTB-positive results, 2.3% (163)
were RIF indeterminate. Unless there was some DR-TB
risk, first-line treatment was started on patients with RIF-
indeterminate results and a repeat MTB/RIF test was not
performed.
Failed tests
The overall failed test rate was 10.6% (range 5.9% in
Moldova and Pakistan to 16.3% in the DRC). When data
was pulled directly from the GeneXpert machine as op-
posed to the laboratory registers, a number of unreported
failed tests were discovered. It appeared that technicians
may have re-tested specimens until a positive or negative
result was achieved, and reported only the final result.
More than one quarter of failed tests were directly related
to power issues, either through No Result outcomes or
2127 Errors but varied greatly by country.
A common test-related error was that of signal loss
associated with an earlier version of MTB/RIF cartridges
(G3 vs G4). Signal loss errors made up 44% of all errors in
Nepal and 28% in DRC, but only 11% in Pakistan (data not
shown) and appeared to be related to specific batches of
G3 cartridges rather than a general problem. In Kenya,
Error rates were much higher among G3 tests (12.9% vs
5.2%), but in other countries there were a higher propor-
tion of Error results among the G4 cartridges. Error results
made up the majority of the failed tests (64.7%), however
in some sites No Result and Invalid findings contributed
significantly to the failed test results. See Table 2 for des-
criptions and recommendations concerning failed tests.
We were unable to accurately track the exact rates of
retesting among the projects as laboratories attempted to
use the same sputum sample, but with referred samples
follow up was often difficult and this information was not
well documented.
The overall module failure rate in the projects was 42%
(77/182), but in Moldova only 7% (5 of 68) modules needed
replacement while in Mozambique, Nepal and Malawi
more than half needed to be replaced. In Bangladesh and
Pakistan all modules needed to be replaced. This was not
just calibrated modules but overall failure. Many module
problems seemed to be clustered suggesting that other im-
plementation issues, such as irregular power supply and
currents, dust build-up, overheating, and staff quality con-
trol may have contributed to the failures.
Rifampicin resistance
Among all valid tests, 2.3% of results showed rifampicin
resistance, (0.9% excluding Moldova). Overall, 13.6%
(n = 982) of MTB-positive results were resistant to rifam-
picin, with Moldova accounting for 69.5% of those cases
and Nepal accounting for 10.6%. Excluding Moldova, 5.6%
of MTB-positive results were resistant to rifampicin. Pro-
jects referred the patients to the MDR-TB treatment sites
but did not generally provide active follow-up as TB
REACH does not provide any funding for drug resistance
treatment or support. Complete data on follow-up culture
and DST were not available for many of the projects as
almost all samples were sent to distant referral laborato-
ries. Projects in Mozambique, DRC, Malawi and Nepal
noted important barriers in getting DST results due to
distance, and overworked laboratories. Most noted signifi-
cant loss to follow-up of patients having to travel long dis-
tances though it was not quantified. Algorithms for
treatment of people with a rifampicin resistant result var-
ied. In settings where there are high levels of DR-TB, such
as Moldova, any patient with a rifampicin resistant result
was placed on a standardized second line treatment regi-
men immediately, reducing the treatment delay signifi-
cantly over the previous system of consolidating samples
and follow-up DST. In settings where drug resistance was
less prevalent, confirmatory DST was requested before pa-
tients started second line regimens. Most patients who
had a prior treatment history were able to initiate second
line treatment immediately. Patients with identified rifam-
picin resistance through MTB/RIF testing would most
likely not have been diagnosed with DR-TB in the absence
of such testing until they had failed treatment or relapsed,
as the projects targeted people with no history of TB and
with limited access to conventional DST methods.
Recording and reporting
All of these nine implementers were among the first to
use MTB/RIF testing in their country and/or were the first
to use it in a programmatic setting. When NTP reporting
guidelines for MTB/RIF testing existed, they were often
for diagnostic algorithms focused on detecting drug resis-
tance, and were inadequate for these case-finding inter-
ventions. The projects in Cambodia and DRC were run by
national and provincial TB programs respectively and had
the ability to set recording guidelines. Cambodia records
all MTB-positive results as smear-positive, while in DRC
and Mozambique they are recorded as smear-negative. In
other countries, reporting procedures had to be discussed
with the NTP and the lack of global guidance on the issue
at the time of testing created some confusion. In Pakistan,
MTB-positive patients were at first reported as smear-
positive, but following changes in NTP guidelines, they
were subsequently reported as smear-negative. In Nepal,
patients detected on the MTB/RIF assay were reported as
smear-negative, but when patients had MTB-positive
results with no CXR result, treatment was initially delayed
due to confusion around guidelines. Malawi had no
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national guidelines for reporting MTB/RIF results, leading
to variable practices among districts until implementing
partners developed standard guidelines.
Projects took advantage of the fact that all machines are
coupled with a computer to develop electronic registers,
but there was general agreement that the pre-installed
GeneXpert Dx software is not useful for capturing patient
cohort information due to test data being individually
processed with limited collating and exporting options.
All projects used different locally developed databases to
track tests and patients. Most projects enforced strict pro-
hibitions on the use of external drives with the computers
due to virus and malware threats. Data were downloaded
from the machines via blank CDs or abstracted through
automated reporting systems. DRC, Kenya, Pakistan and
Bangladesh employed systems that provided immediate
reporting of test results to the providers and referral sys-
tems over a GSM network.
Discussion and conclusions
The findings of this study begin to fill the gaps among
guidelines, research findings, and real-world implementa-
tion of MTB/RIF testing, where NTPs and their partners
work to test people with suspected TB and drug resis-
tance. The projects documented here had a wide range of
experiences, approaches and results, demonstrating the
versatility of Xpert MTB/RIF, but also highlighting a num-
ber of barriers to implementation and possible solutions.
As others have pointed out, the technology has great
potential, but also has important limitations. This study
begins to address some of the concerns delineated
through implementation experiences in the field. These
projects have showed that with proper support for pro-
curement, infrastructure and supervision, Xpert MTB/RIF
can be deployed at or very close to the point of care in
many settings initially considered difficult because of the
hurdles to overcome [26]. Our findings generally coincide
with other early assessments of the challenges and benefits
of Xpert MTB/RIF implementation where many barriers
can be surmounted if proper systems are in place and a
coordinated country approach is taken with the best inter-
ests of the patient in mind [27].
Xpert MTB/RIF testing detected a large number of
people with TB that routine services failed to detect.
Data from South Africa shows similar results for MTB-
positive yield but much lower error rates [28] although
many of the projects described here placed the machines
in different types of facilities, including mobile units and
primary care facilities in challenging settings. When
available, the use of CXR as a highly sensitive screening
tool should be considered before testing with Xpert
MTB/RIF, to save cartridges and increase yield [2,29].
Placing smear microscopy ahead of the MTB/RIF test in
the diagnostic algorithm often resulted in lower yields
compared with specimens tested directly on the MTB/RIF
assay, as smear-positive patients were then excluded.
However, the underlying prevalence of TB in the screened
population, as well as the quality of smear microscopy
services [30], play important roles in influencing yields
among smear-negative specimens. Xpert MTB/RIF testing
on smear-negative individuals, the general approach used
here, expends significantly more resources and time, as all
individuals are tested using smear microscopy and 80-90%
of them are re-tested with Xpert MTB/RIF. New WHO
guidance recommends that Xpert MTB/RIF replace smear
microscopy when resources allow [31]. All of the projects
described here had external funding for Xpert MTB/RIF
testing and so it is curious that only a few used it to
replace smear, but this was many times limited by national
policy.
Tracking the types, codes, reason, locations, and techni-
cians associated with failed tests is important for users to
improve performance. There are generally three possible
types of failed tests for MTB/RIF: human, power supply
and test-related. Human errors generally arose from inad-
equate sputum collection or specimen preparation and
can be tracked by their numeric code [32]. Automated
reporting mechanisms can improve both the timeliness
and accuracy of reporting errors and all results as well
assist in supply chain management [33]. Some projects
had very high rates of Invalid results which seem to be
caused by problems with the quality of the sputum sample
and proper mouth cleansing techniques. Better coaching
from staff may be able to help in these instances. While
the failed test rates are much higher than in South Africa,
they are similar to some other larger early implementer
multi-country initiatives [34]. Most of the projects placed
the machines at lower level facilities which presents more
of a challenge for implementation and supervision. An
early experience in South Africa using mobile testing had
comparable failed test results, although most were power
supply related. [Personal Communication Liesl Page-Shipp]
No result outcomes are often linked to power supply pro-
blems. In environments with irregular and unpredictable
power, a backup power supply with an inverter should be
capable of supporting the GeneXpert machine and com-
puter for at least 2 hours in order to finish any test begun
before a power failure (see Table 2). When GeneXpert ma-
chines are placed in facilities with other equipment need-
ing power supply, generators are likely to be available and
backup power may only be needed until the generator can
be started. Ensuring timely calibration of the GeneXpert
machines will also reduce errors. If the calibration is done
after the module warranty expires and the module must
be replaced, a new module or an extended warranty must
be purchased. Modules can still fail outside of calibration
and extended warrantees are available and should be pur-
chased to protect the users.
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As Xpert MTB/RIF provides both TB and rifampicin re-
sistance results, it is important to weigh the benefit of
early detection of drug resistance against the concern that
large increases in DR-TB detection would overwhelm ad-
vanced diagnostic facilities and nascent drug-resistant TB
treatment programs. Focusing MTB/RIF testing solely on
DR-TB suspects is unlikely to produce large yields as the
numbers of failures and retreatment cases at a district
level is quite small in most settings. Furthermore, the ma-
jority of DR-TB cases will be found among new cases [35],
requiring testing of people with suspected TB rather than
patients already receiving TB treatment if meaningful
MDR-TB treatment scale up is to take place. The applica-
tion of algorithms focused on people with suspected TB
will generally result in large increases in drug sensitive
cases detected and a lower proportion of rifampicin resis-
tant results. Nevertheless, DR-TB patients will be detected
in greater numbers and with greater speed than under
current conditions, and significant resources and coor-
dination will be required for treatment, especially if
MTB/RIF testing is to be done in areas without DR-TB
treatment capacity as was the case in many of these pro-
jects. These projects were limited given funding was not
provided for DR-TB treatment and active follow-up of rifi-
mapicin resistant patients was generally not conducted
and data is limited. However, in many countries, overall
donor funding for DR-TB treatment remains unused as
many people with DR-TB have not been diagnosed; so
opportunities for expansion exist. Given the concern
about slow expansion of MDR-TB treatment globally,
South Africa has clearly shown that huge gains in detec-
tion and notification are possible in a short period of time
using Xpert MTB/RIF as the primary diagnostic tool [1].
Apart from testing approaches and results, there were a
number of other implementation issues that merit discus-
sion. Although many point of care testing strategies focus
on finger prick or dipstick testing, a recent review discussed
the positioning of diagnostic tests in the health system and
argued that many tests could be considered point of care,
including smear microscopy and MTB/RIF, if the test and
treat cycle could be completed in the same clinical encoun-
ter (or the same day) [36]. However, testing algorithms and
work-flow practices often gets in the way of providing quick
results to the patient and ensuring same-day TB treatment
and this was seen in a number of projects [36]. While
Xpert MTB/RIF testing can provide highly sensitive results
quickly in a number of different settings, the health system
must provide a supportive environment; tightly controlling
the machine and testing in high level laboratories may
sometimes be achieved to the detriment of the patient. A
recent study has made a strong argument for the use of
MTB/RIF as a point-of-care test showing a reduction in
delay, empiric treatment, and the ability of nurses to imple-
ment the test in primary care settings [37].
Decisions on machine location should be given careful
consideration with respect to expected numbers of people
tested and the need for referral systems in addition to
power supply. Although many peripheral health facilities
do not have the infrastructure to handle complicated tes-
ting [38], the main limitations we identified for decentra-
lized MTB/RIF testing - algorithms, power, temperature
and numbers of tests expected - can all be overcome with
proper support, although in some remote areas supervi-
sion is difficult and seemed to complicate performance.
Training staff to use GeneXpert equipment was gener-
ally described as straightforward, supporting views of
other early implementers [39]. However, the need for
retraining and supervision cannot be overlooked as staff
turnover is a constant reality. As part of training, ensu-
ring solidified national testing and treatment guidelines
are in place is critical. Country adoption of the WHO
policy guidance around testing algorithms [2] as well as
recent WHO new case and outcome definitions incor-
porating MTB/RIF and other WHO recommended tests
[40], will greatly help standardize the process. All people
with MTB/RIF positive results should be recorded as
bacteriologically positive cases. The adoption of WHO
recommended strategies and reporting systems will re-
duce the inconsistencies that the early implementers
faced, though it must be acknowledged that field adop-
tion of new guidance often takes time. Delays in customs
clearing, in country transportation and other preparatory
activities, such as training, will shorten the effective
usage time for the cartridges. Staggering orders can help
avoid expiry of cartridges, which have a short shelf life.
The technology has the possibility of being quite dis-
ruptive to national testing and treatment policy, and to
recording and reporting forms and training. With do-
nors including PEPFAR and The Global Fund begin-
ning to fund the expansion of MTB/RIF testing in
many countries, lessons learned from pilot projects that
can be applied to a large expansion of testing must be
disseminated. One of the main areas of concern about
MTB/RIF testing is the additional cost to country diag-
nostic budgets which these projects did not have to ad-
dress as the work was grant funded, therefore this
experience cannot directly address or inform those con-
cerns. Just as a few countries fund their own second
line treatment programs, we feel that the benefits of
improved diagnostics for TB and drug-resistant TB
provide ample justification for long term support of im-
proved diagnostics from donors. This study is not rep-
resentative of all early implementer experiences with
MTB/RIF testing but rather provides an overview of
the shared issues across countries and of many different
approaches to MTB/RIF implementation on a program-
matic basis. Further programmatic studies are needed on
issues such as case notification, time to diagnosis, cost
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effectiveness of MTB/RIF use in case finding programs
and use at the most peripheral of health units (point of
care testing) - all issues that our work was not designed to
answer.
The experiences of these early implementers show that
a variety of MTB/RIF testing approaches can be success-
fully employed across many different settings. This early
information can be usefully applied in the on-going
global scale up of MTB/RIF. The MTB/RIF test has limi-
tations, but also provides an excellent opportunity to im-
prove the way TB and drug-resistant TB are diagnosed
on a wide scale.
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